Canadian Alternatives in Non-invasice Ventilation Program, Respiratory Services and The Ottawa Hospital Sleep Centre, Ottawa, Ontario, Canada.
Can Respir J. 2013 Jan-Feb;20(1):e5-9. doi: 10.1155/2013/406163.
Almost all patients with Duchenne muscular dystrophy (DMD) eventually develop respiratory failure. Once 24 h ventilation is required, either due to incomplete effectiveness of nocturnal noninvasive ventilation (NIV) or bulbar weakness, it is common practice to recommend invasive tracheostomy ventilation; however, noninvasive daytime mouthpiece ventilation (MPV) as an addition to nocturnal mask ventilation is also an alternative.
The authors' experience with 12 DMD patients who used 24 h NIV with mask NIV at night and MPV during daytime hours is reported.
The mean (± SD) age and vital capacity (VC) at initiation of nocturnal (only) NIV subjects were 17.8±3.5 years and 0.90±0.40 L (21% predicted), respectively; and, at the time of MPV, 19.8±3.4 years and 0.57 L (13.2% predicted), respectively. In clinical practice, carbon dioxide (CO2) levels were measured using different methods: arterial blood gas analysis, transcutaneous partial pressure of CO2 and, predominantly, by end-tidal CO2. While the results suggested improved CO2 levels, these were not frequently confirmed by arterial blood gas measurement. The mean survival on 24 h NIV has been 5.7 years (range 0.17 to 12 years). Of the 12 patients, two deaths occurred after 3.75 and four years, respectively, on MPV; the remaining patients continue on 24 h NIV (range two months to 12 years; mean 5.3 years; median 3.5 years).
Twenty-four hour NIV should be considered a safe alternative for patients with DMD because its use may obviate the need for tracheostomy in patients with chronic respiratory failure requiring more than nocturnal ventilation alone.
几乎所有杜氏肌营养不良症(DMD)患者最终都会发展为呼吸衰竭。一旦需要 24 小时通气,无论是由于夜间无创通气(NIV)不完全有效还是延髓无力,通常都会建议进行有创气管造口通气;但是,作为夜间面罩通气的补充,无创日间口罩通气(MPV)也是一种选择。
作者报告了 12 例 DMD 患者的经验,这些患者使用夜间面罩 NIV 进行 24 小时 NIV,白天则使用 MPV。
仅夜间 NIV 起始时的平均(± SD)年龄和肺活量(VC)分别为 17.8±3.5 岁和 0.90±0.40 L(预测值的 21%);而在开始使用 MPV 时,分别为 19.8±3.4 岁和 0.57 L(预测值的 13.2%)。在临床实践中,二氧化碳(CO2)水平是通过不同的方法测量的:动脉血气分析、经皮 CO2分压,主要是通过呼气末 CO2。虽然结果表明 CO2 水平有所改善,但这些结果并未经常通过动脉血气测量得到证实。24 小时 NIV 的平均生存时间为 5.7 年(范围 0.17 至 12 年)。在 12 例患者中,有 2 例分别在开始使用 MPV 后 3.75 年和 4 年死亡;其余患者继续使用 24 小时 NIV(范围为 2 个月至 12 年;平均 5.3 年;中位数 3.5 年)。
24 小时 NIV 应被视为 DMD 患者的安全替代方案,因为它的使用可以避免需要对需要超过夜间通气的慢性呼吸衰竭患者进行气管造口术。